Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of “Buy” by Brokerages

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have been given an average rating of “Buy” by the nine analysts that are covering the company, Marketbeat reports. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $46.83.

DNTH has been the topic of a number of recent research reports. Oppenheimer raised their price objective on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research note on Monday, November 11th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Monday, November 11th. TD Cowen began coverage on shares of Dianthus Therapeutics in a research note on Friday, December 20th. They issued a “buy” rating on the stock. Finally, Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. R Squared Ltd acquired a new stake in shares of Dianthus Therapeutics during the fourth quarter worth $26,000. Quest Partners LLC raised its holdings in shares of Dianthus Therapeutics by 112,400.0% during the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after acquiring an additional 1,124 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in shares of Dianthus Therapeutics during the fourth quarter worth $33,000. KBC Group NV acquired a new stake in shares of Dianthus Therapeutics during the fourth quarter worth $35,000. Finally, BNP Paribas Financial Markets acquired a new stake in shares of Dianthus Therapeutics during the fourth quarter worth $59,000. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Price Performance

DNTH opened at $23.34 on Friday. Dianthus Therapeutics has a one year low of $18.34 and a one year high of $33.77. The stock has a market capitalization of $690.86 million, a P/E ratio of -9.34 and a beta of 1.72. The company’s 50 day simple moving average is $22.89 and its 200-day simple moving average is $25.54.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.